Go Pro
→ Trump’s emergency dollar reset (From Porter & Company) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
Compare

SMFL vs. ADTX, CMRA, EFTR, SYRS, and EVLO

Should you buy Smart for Life stock or one of its competitors? MarketBeat compares Smart for Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Smart for Life include Aditxt (ADTX), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), Syros Pharmaceuticals (SYRS), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry.

How does Smart for Life compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Aditxt has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Smart for Life has a beta of 15.05, indicating that its share price is 1,405% more volatile than the broader market.

In the previous week, Aditxt had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for Smart for Life. Aditxt's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Aditxt Neutral
Smart for Life Neutral

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Smart for Life N/A N/A N/A

Smart for Life has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aditxt$14.34K0.14-$41.71M-$100.79 thousandN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Given Smart for Life's higher possible upside, analysts plainly believe Smart for Life is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Smart for Life beats Aditxt on 10 of the 13 factors compared between the two stocks.

How does Smart for Life compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Smart for Life (NASDAQ:SMFL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Comera Life Sciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Smart for Life has a beta of 15.05, suggesting that its share price is 1,405% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Smart for Life N/A N/A N/A

Comera Life Sciences has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to eFFECTOR Therapeutics?

Smart for Life (NASDAQ:SMFL) and eFFECTOR Therapeutics (NASDAQ:EFTR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Smart for Life has a beta of 15.05, indicating that its share price is 1,405% more volatile than the broader market. Comparatively, eFFECTOR Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 4.7% of eFFECTOR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled eFFECTOR Therapeutics'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
eFFECTOR Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Syros Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, earnings, profitability and institutional ownership.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals had 2 more articles in the media than Smart for Life. MarketBeat recorded 2 mentions for Syros Pharmaceuticals and 0 mentions for Smart for Life. Smart for Life's average media sentiment score of 0.00 equaled Syros Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Syros Pharmaceuticals Neutral

Smart for Life's return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Syros Pharmaceuticals N/A -3,369.56%-97.04%

Smart for Life has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A

Smart for Life has a beta of 15.05, indicating that its stock price is 1,405% more volatile than the broader market. Comparatively, Syros Pharmaceuticals has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market.

Summary

Smart for Life beats Syros Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

How does Smart for Life compare to Evelo Biosciences?

Smart for Life (NASDAQ:SMFL) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Evelo Biosciences Neutral

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Evelo Biosciences N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Smart for Life has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A

Smart for Life has a beta of 15.05, suggesting that its share price is 1,405% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

Summary

Smart for Life beats Evelo Biosciences on 6 of the 7 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifeMedicinals & botanicals IndustryMedical SectorNASDAQ Exchange
Market Cap$1K$5.34B$6.86B$12.27B
Dividend YieldN/AN/A2.67%9.36%
P/E Ratio0.0012.0527.2523.92
Price / SalesN/A2.84580.44113.62
Price / CashN/A7.1529.0548.09
Price / BookN/A2.1510.596.18
Net Income-$22.68M$33.20M$3.59B$331.89M

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/AN/AN/AN/A$1K$11.11MN/A110
ADTX
Aditxt
0.579 of 5 stars		$0.00
-9.1%		N/A-100.0%$3K$14.34KN/A60
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$3KN/AN/A10
SYRS
Syros Pharmaceuticals
N/A$0.00
flat		N/A-99.0%$3K$386KN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 7/20/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Not oil. Not solar. Bigger.
The International Energy Agency measured it at 140 times global electricity demand. It runs 24 hours a day, pr...
Behind the Markets | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel